Alteration of amino acid residues at the L-chain N-terminus and in complementarity-determining region 3 increases affinity of a recombinant F(ab) for the human N blood group antigen

Transfusion

Volumn 44, Issue 2, 2004, Pages 173-186

  Song, Shuh Chyuny ^b   Czerwinski, Marcin ^b   Wojczyk, Boguslaw S ^b   Spitalnik, Steven L ^a  

^a Coll of Phys/Surgs Columbia Univ ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BLOOD GROUP ANTIGEN; GLYCOPEPTIDE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY AFFINITY; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD GROUP MNSS SYSTEM; BLOOD GROUP SYSTEM; CHO CELL; COMPLEMENTARITY DETERMINING REGION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; SITE DIRECTED MUTAGENESIS;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CHO CELLS; COMPLEMENTARITY DETERMINING REGIONS; CRICETINAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEMAGGLUTINATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MUTAGENESIS; NEOPLASM PROTEINS; PROTEIN STRUCTURE, TERTIARY; TRANSFECTION;

EID: 1242344738     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2004.00625.x     Document Type: Article

References (72)

1. Spiro RG. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 2002;12:43R-56R.
2. Karsten U, Diotel C, Klich G, et al. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation. Cancer Res 1998;58:2541-9.
3. Hanisch FG, Stadie T, Bosslet K. Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine within the VTSA motif of MUC1 tandem repeats. Cancer Res 1995;55:4036-40.
4. Matsuura H, Greene T, Hakomori S. An alpha-N-acetylgalactosaminylation at the threonine residue of a defined peptide sequence creates the oncofetal peptide epitope in human fibronectin. J Biol Chem 1989;264:10472-6.
5. Blackall DP, Ugorski M, Pahlsson P, Shakin-Eshleman SH, Spitalnik SL. A molecular biologic approach to study the fine specificity of antibodies directed to the MN human blood group antigens. J Immunol 1994;152:2241-7.
6. Blackall DP, Ugorski M, Smith ME, Pahlsson P, Spitalnik SL. The binding of human alloantibodies to recombinant glycophorin A. Transfusion 1992;32:629-32.
7. Czerwinski M, Blackall DP, Abrams WR, Rubocki RJ, Spitalnik SL. Restricted VH gene usage by murine hybridomas directed against the human N, but not M, blood group antigen. Mol Immunol 1994;31:279-88.
8. Czerwinski M, Krop-Watorek A, Lisowska E, Spitalnik SL. Construction of dimeric F(ab) useful in blood group serology. Transfusion 2002;42:257-64.
9. Czerwinski M, Krop-Watorek A, Siegel DL, Spitalnik SL. A molecular approach for isolating high-affinity Fab fragments that are useful in blood group serology. Transfusion 1999;39:364-71.
10. Czerwinski M, Siegel DL, Moore JS, Spitalnik PF, Spitalnik SL. Construction of bacteriophage expressing mouse monoclonal Fab fragments directed against the human MN glycophorin blood group antigens. Transfusion 1995;35:137-44.
11. Czerwinski M, Siemaszko D, Siegel DL, Spitalnik SL. Only selected light chains combine with a given heavy chain to confer specificity for a model glycopeptide antigen. J Immunol 1998;160:4406-17.
12. Remaley AT, Ugorski M, Wu N, et al. Expression of human glycophorin A in wild type and glycosylation-deficient Chinese hamster ovary cells: role of N- and O-linked glycosylation in cell surface expression. J Biol Chem 1991; 266:24176-83.
13. Pahlsson P, Blackall DP, Ugorski M, Czerwinski M, Spitalnik SL. Biochemical characterization of the O-glycans on recombinant glycophorin A expressed in Chinese hamster ovary cells. Glycoconj J 1994;11:43-50.
14. Telischi M, Behzad O, Issitt PD, Pavone BG. Hemolytic disease of the newborn due to anti-N. Vox Sang 1976;31:109-16.
15. Sancho JM, Pujol M, Fernandez F, et al. Delayed haemolytic transfusion reaction due to anti-M antibody. Br J Haematol 1998;103:268-9.
16. Parry-Jones N, Gore ME, Taylor J, Treleaven JG. Delayed haemolytic transfusion reaction caused by anti-M antibody in a patient receiving interleukin-2 and interferon for metastatic renal cell cancer. Clin Lab Haematol 1999;21: 407-8.
17. Matsumoto H, Tamaki Y, Sato S, Shibata K. A case of hemolytic disease of the newborn caused by anti-M: serological study of maternal blood. Acta Obstet Gynaecol Jpn 1981;33:525-8.
18. Wasniowska K, Drzeniek Z, Lisowska E. The amino acids of M and N blood group glycopeptides are different. Biochem Biophys Res Commun 1976;76:385-90.
19. Blumenfeld OO, Adamany AM. Structural polymorphism within the amino-terminal region of MM, NN, and MN glycoproteins (glycophorins) of the human erythrocyte membrane. Proc Natl Acad Sci U S A 1978;75:2727-31.
20. Tomita M, Marchesi VT. Amino-acid sequence and oligosaccharide attachment sites of human erythrocyte glycophorin. Proc Natl Acad Sci U S A 1975;72:2964-8.
21. Lisowska E, Duk M, Dahr W. Comparison of alkal-labile oligosaccharide chains of M and N blood-group glycopeptides from human erythrocyte membrane. Carbohydr Res 1980;79:103-13.
22. Thomas DB, Winzler RJ. Structural studies on human erythrocyte glycoproteins: alkali-labile oligosaccharides. J Biol Chem 1969;244:5943-6.
23. Duk M, Sticher U, Brossmer R, Lisowska E. The differences in significance of alpha 2,3Gal-linked and alpha2,6GalNAc-linked sialic acid residues in blood group M- and N-related epitopes recognized by various monoclonal antibodies. Glycobiology 1994;4:175-81.
24. Lisowska E, Messeter L, Duk M, Czerwinski M, Lundblad A. A monoclonal anti-glycophorin A antibody recognizing the blood group M determinant: studies on the subspecificity. Mol Immunol 1987;24:605-13.
25. Wasniowska K, Duk M, Steuden I, et al. Two monoclonal antibodies recognizing different epitopes of blood group N antigen. Arch Immunol Ther Exp (Warsz) 1988;36:623-32.
26. Jaskiewicz E, Moulds JJ, Kraemer K, Goldstein AS, Lisowska E. Characterization of the epitope recognized by a monoclonal antibody highly specific for blood group M antigen. Transfusion 1990;30:230-5.
27. Jaskiewicz E, Czerwinski M, Syper D, Lisowska E. Anti M monoclonal antibodies cross-reacting with variant Mg antigen: an example of modulation of antigenic properties of peptide by its glycosylation. Blood 1994;84:2340-5.
28. Rubocki R, Milgrom F. Reactions of murine monoclonal antibodies to blood group MN antigens. Vox Sang 1986;51: 217-25.
29. Bigbee WL, Langlois RG, Vanderlaan M, Jensen RH. Binding specificities of eight monoclonal antibodies to human glycophorin A-studies with McM, and MkEn (UK) variant human erythrocytes and M- and MNV-type chimpanzee erythrocytes. J Immunol 1984;133:3149-55.
30. Bigbee WL, Vanderlaan M, Fong SS, Jensen RH. Monoclonal antibodies specific for the M- and N-forms of human glycophorin A. Mol Immunol 1983;20:1353-62.
31. Anstee DJ, Edwards PA. Monoclonal antibodies to human erythrocytes. Eur J Immunol 1982;12:228-32.
32. Anstee DJ, Lisowska E. Monoclonal antibodies against glycophorins and other glycoproteins. J Immunogenet 1990;17:301-8.
33. Rasamoelisolo M, Czerwinski M, Bruneau V, Lisowska E, Blanchard D. Fine characterization of a series of new monoclonal antibodies directed against glycophorin A. Vox Sang 1997;72:185-91.
34. Judd WJ, Issitt PD, Pavone BG, Anderson J, Aminoff D. Antibodies that define NANA-independent MN-system antigens. Transfusion 1979;19:12-8.
35. Sadler JE, Paulson JC, Hill RL. The role of sialic acid in the expression of human MN blood group antigens. J Biol Chem 1979;254:2112-9.
36. Huang CH, Johe KK, Seifter S, Blumenfeld OO. Biochemistry and molecular biology of MNSs blood group antigens. Baillieres Clin Haematol 1991;4:821-48.
37. Chasis JA, Mohandas N. Red blood cell glycophorins. Blood 1992;80:1869-79.
38. Lu YQ, Nichols ME, Bigbee WL, Nagel RL, Blumenfeld OO. Structural polymorphism of glycophorins demonstrated by immunoblotting techniques. Blood 1987;69:618-24.
39. Emanuelsson O, von Heijne G. Prediction of organellar targeting signals. Biochim Biophys Acta 2001;1541:114-9.
40. Gao QS, Sun M, Rees AR, Paul S. Site-directed mutagenesis of proteolytic antibody light chain. J Mol Biol 1995;253:658-64.
41. Crouzier R, Martin T, Pasquali JL. Heavy chain variable region, light chain variable region, and heavy chain CDR3 influences on the mono- and polyreactivity and on the affinity of human monoclonal rheumatoid factors. J Immunol 1995;154:4526-35.
42. Dall'Acqua W, Goldman ER, Eisenstein E, Mariuzza RA. A mutational analysis of the binding of two different proteins to the same antibody. Biochemistry 1996;35:9667-76.
43. Rosok MJ, Eghtedarzadeh-Kondri M, Young K, et al. Analysis of BR96 binding sites for antigen and anti-idiotype by codon-based scanning mutagenesis. J Immunol 1998;160: 2353-9.
44. Thompson J, Pope T, Tung JS, et al. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. J Mol Biol 1996;256:77-88.
45. Ichiyoshi Y, Casali P. Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments. J Exp Med 1994;180:885-95.
46. Barry MM, Lee JS. Cloning and expression of an autoimmune DNA-binding single chain Fv: only the heavy chain is required for binding. Mol Immunol 1993;30: 833-40.
47. Chatellier J, Van Regenmortel MH, Vernet T, Altschuh D. Functional mapping of conserved residues located at the VL and VH domain interface of a Fab. J Mol Biol 1996;264:1-6.
48. Augustine JG, de La Calle A, Knarr G, Buchner J, Frederick CA. The crystal structure of the Fab fragment of the monoclonal antibody MAK33: implications for folding and interaction with the chaperone Bip. J Biol Chem 2001;276: 3287-94.
49. Ohlin M, Owman H, Mach M, Borrebaeck CA. Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Mol Immunol 1996;33:47-56.
50. Song MK, Oh MS, Lee JH, et al. Light chain of natural antibody plays a dominant role in protein antigen binding. Biochem Biophys Res Commun 2000;268:390-4.
51. Suzuki M, Takemura H, Suzuki H, Sumida T. Light chain determines the binding property of human anti-dsDNA IgG autoantibodies. Biochem Biophys Res Commun 2000;271: 240-3.
52. Paul S, Sun M, Mody R, et al. Peptidolytic monoclonal antibody elicited by a neuropeptide. J Biol Chem 1992;267: 13142-5.
53. Herron JN, He XM, Mason ML, Voss EW Jr, Edmundson AB. Three-dimensional structure of a fluorescein-Fab complex crystallized in 2-methyl-2,4-pentanediol. Proteins 1989;5: 271-80.
54. Whitlow M, Howard AJ, Wood JF, Voss EW Jr, Hardman KD. A structure of anti-fluorescein 4-4-20 Fab. Protein Eng 1995;8:749-61.
55. Guddat LW, Shan L, Anchin JM, Linthicum DS, Edmundson AB. Local and transmitted conformational changes on complexation of an anti-sweetener Fab. J Mol Biol 1994; 236:247-74.
56. Shoham M. Crystal structure of an anticholera toxin peptide complex at 2.3 A. J Mol Biol 1993;232:1169-75.
57. Chothia C, Lesk AM, Tramontano A, et al. Conformations of immunoglobulin hypervariable regions. Nature 1989;342: 877-83.
58. Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997;273:927-48.
59. Wu TT, Kabat EA. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 1970;132:211-50.
60. Mian IS, Bradwell AR, Olson AJ. Structure, function and properties of antibody binding sites. J Mol Biol 1991;217: 133-51.
61. Padlan EA, Abergel C, Tipper JP. Identification of specificity-determining residues in antibodies. FASEB J 1995;9: 133-9.
62. Padlan EA. On the nature of antibody combining sites: unusual structural features that may confer on these sites an enhanced capacity for binding ligands. Proteins 1990;7:112-24.
63. Braden BC, Goldman ER, Mariuzza RA, Poljak RJ. Anatomy of an antibody molecule: structure, kinetics, thermodynamics and mutational studies of the antilysozyme antibody D1. Immunol Rev 1998;163:45-57.
64. Jin L, Fendly BM, Wells JA. High resolution functional analysis of antibody-antigen interactions. J Mol Biol 1992; 226:851-65.
65. Chothia C, Gelfand I, Kister A. Structural determinants in the sequences of immunoglobulin variable domain. J Mol Biol 1998;278:457-79.
66. Ping J, Schildbach JF, Shaw SY, et al. Effect of heavy chain signal peptide mutations and NH2-terminal chain length on binding of anti-digoxin antibodies. J Biol Chem 1993;268: 23000-7.
67. Saviranta P, Jauria P, Lamminmaki U, et al. N-terminal mutations in the anti-estradiol Fab 57-2 modify its hapten binding properties. Protein Sci 2000;9:2547-56.
68. Schable KF, Thiebe R, Bensch A, et al. Characteristics of the immunoglobulin V kappa genes, pseudogenes, relics and orphons in the mouse genome. Eur J Immunol 1999;29: 2082-6.
69. Seibel JL, Wilson N, Kozono H, Marrack P, Kappler JW. Influence of the NH2-terminal amino acid of the T cell receptor alpha chain on major histocompatibility complex (MHC) class II+ peptide recognition. J Exp Med 1997;185: 1919-27.
70. Padlan EA, Davies DR. Variability of three-dimensional structure in immunoglobulins. Proc Natl Acad Sci U S A 1975;72:819-23.
71. Corbet S, Milili M, Fougereau M, Schiff C. Two V kappa germline genes related to the GAT idiotypic network (Ab1 and Ab3/Ab1′) account for the major subfamilies of the mouse V kappa-1 variability subgroup. J Immunol 1987;138: 932-9.
72. Kabat EA, Wu TT, Bilofsky H. Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites. J Biol Chem 1977;252:6609-16.